0001104659-24-044767.txt : 20240408 0001104659-24-044767.hdr.sgml : 20240408 20240408163837 ACCESSION NUMBER: 0001104659-24-044767 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240408 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240408 DATE AS OF CHANGE: 20240408 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Milestone Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001408443 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38899 FILM NUMBER: 24830077 BUSINESS ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 BUSINESS PHONE: (514) 336-0444 MAIL ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 8-K 1 tm2411306d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

April 8, 2024

MILESTONE PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Québec		001-38899		Not applicable
(state or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1111 Dr. Frederik-Philips Boulevard,
Suite 420
Montréal, Québec CA		H4M 2X6
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (514) 336-0444

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares		MIST		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 8.01.

Other Events.

On April 8, 2024, Milestone Pharmaceuticals Inc. issued a press release announcing new clinical data demonstrating real-world application of etripamil for conversion of paroxysmal supraventricular tachycardia. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01.

Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	Description
99.1	Press release, dated April 8, 2024.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MILESTONE PHARMACEUTICALS INC.

Date: April 8, 2024	By:	/s/ Amit Hasija
		Amit Hasija
		Chief Financial Officer Principal Financial Officer

EX-99.1 2 tm2411306d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Data from this large safety-trial also published in The Journal of the American College of Cardiology

Montreal and Charlotte, N.C., April 8, 2024 -- Milestone^® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced new clinical data demonstrating real-world application of etripamil, an investigational new drug, for conversion of recurrent paroxysmal supraventricular tachycardia (PSVT).

“The promising results of this real-world design study demonstrated patients’ ability to self-manage multiple episodes of PSVT with etripamil,” said David Bharucha, MD, PhD, FACC, Chief Medical Officer of Milestone Pharmaceuticals. “These data, coupled with our prior published etripamil Phase 3 studies, completes an exceptionally large data package assessing acute treatment of PSVT in the at-home setting.”

Conducted in North and South America, this open label, Phase 3 study of etripamil in PSVT today was both presented at The American College of Cardiology Scientific Sessions in Atlanta, GA and published in The Journal of the American College of Cardiology. CARDAMYST^™, the conditionally approved brand name for etripamil nasal spray, if approved, will be the first rapid, reliable, and at-the-ready option in the acute treatment of PSVT.

NODE-303 (ClinicalTrials.gov ID NCT04072835) evaluated self-administered etripamil (70 mg, nasal spray) in an outpatient setting for up to multiple episodes of PSVT, without prior test dosing. It did not exclude patients with a history of co-morbid atrial fibrillation (AFib) or atrial flutter. The results demonstrated that symptom-prompted treatment with etripamil was effective at restoring sinus rhythm as compared to placebo with a median time-to-conversion of 17.0 minutes and was generally well tolerated. The conversion of PSVT to sinus rhythm was similar among multiple PSVT episodes and the frequency of treatment-emergent adverse events at 24 hours decreased with successive episodes. Adverse events were predominantly localized to the drug’s nasal administration site, consistent with prior trial findings. The protocol was amended during the trial to allow for a repeat dose of drug if symptoms persisted 10 minutes following the first dose. Efficacy of etripamil for PSVT conversion (restoration of sinus rhythm) in NODE-303 was 60% by 30 minutes after drug self-administration, and 69.9% by 60 minutes after drug self-administration; these rates of conversion are similar to those demonstrated in double-blinded and other open-label studies. These data support a potentially significant shift in the management approach for recurrent PSVT.

Both the presentation and publication will be available on the Milestone Pharmaceuticals corporate website at the conclusion of the ACC presentation.

About Paroxysmal Supraventricular Tachycardia

An estimated two million people in the United States are currently diagnosed with PSVT which is a type of arrhythmia or abnormal heart rhythm. PSVT is characterized by episodes of sudden onset rapid heartbeats often exceeding 150 to 200 beats per minute. The heart rate spike is unpredictable and may last several hours. The rapid heart rate often causes disabling severe palpitations, shortness of breath, chest discomfort, dizziness or lightheadedness, and distress, forcing patients to limit their daily activities. The uncertainty of when an episode of PSVT will strike or how long it will persist can provoke anxiety in patients and negatively impact their day-to-day life between episodes. The impact and morbidity from an attack can be especially detrimental in patients with underlying cardiovascular or medical conditions, such as heart failure, obstructive coronary disease, or dehydration. Many health care providers are dissatisfied with the lack of effective treatment options with patients often requiring prolonged, burdensome, and costly trips to the emergency department or even invasive cardiac ablation procedures.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "continue," "could," "demonstrate," "designed," "develop," "estimate," "expect," "may," "pending," "plan," "potential," "progress," "will," “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding patients’ ability to self-manage multiple episodes of PSVT with etripamil; and the potential for etripamil to present a significant shift in the management approach for recurrent PSVT. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether our future interactions with the FDA will have satisfactory outcomes; whether and when, if at all, our NDA for etripamil will be approved by the FDA; whether the FDA will require additional trials or data which may significantly delay and put at risk our efforts to obtain approval and may not be successful, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone's filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 10-K for the year ended December 31, 2023, under the caption "Risk Factors," as such discussion may be updated from time to time by subsequent filings Milestone may make with the U.S. Securities & Exchange Commission. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

Kim Fox, Vice President, Communications, kfox@milestonepharma.com

Investor Relations

Chris Calabrese, ccalabrese@lifesciadvisors.com

Kevin Gardner, kgardner@lifesciadvisors.com

EX-101.SCH 3 mist-20240408.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mist-20240408_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mist-20240408_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2411306d1_ex99-1img001.jpg GRAPHIC begin 644 tm2411306d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Cover

Apr. 08, 2024

Cover [Abstract]

Document Type 8-K

Amendment Flag false

Document Period End Date Apr. 08, 2024

Entity File Number 001-38899

Entity Registrant Name MILESTONE PHARMACEUTICALS INC.

Entity Central Index Key 0001408443

Entity Tax Identification Number 00-0000000

Entity Incorporation, State or Country Code A8

Entity Address, Address Line One 1111 Dr. Frederik-Philips Boulevard

Entity Address, Address Line Two Suite 420

Entity Address, City or Town Montréal

Entity Address, State or Province QC

Entity Address, Country CA

Entity Address, Postal Zip Code H4M 2X6

City Area Code 514

Local Phone Number 336-0444

Written Communications false

Soliciting Material false

Pre-commencement Tender Offer false

Pre-commencement Issuer Tender Offer false

Title of 12(b) Security Common Shares

Trading Symbol MIST

Security Exchange Name NASDAQ

Entity Emerging Growth Company true

Elected Not To Use the Extended Transition Period true

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine2

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
ISO 3166-1 alpha-2 country code.
+ References
No definition available.
+ Details

Name: dei_EntityAddressCountry

Namespace Prefix: dei_

Data Type: dei:countryCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details

Name: dei_PreCommencementIssuerTenderOffer

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details

Name: dei_PreCommencementTenderOffer

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
+ Details

Name: dei_SolicitingMaterial

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details

Name: dei_WrittenCommunications

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://milestonepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, dei:EntityIncorporationStateCountryCode - tm2411306d1_8k.htm 21, 23 mist-20240408.xsd mist-20240408_lab.xml mist-20240408_pre.xml tm2411306d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2411306d1_8k.htm": { "nsprefix": "mist", "nsuri": "http://milestonepharma.com/20240408", "dts": { "schema": { "local": [ "mist-20240408.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "mist-20240408_lab.xml" ] }, "presentationLink": { "local": [ "mist-20240408_pre.xml" ] }, "inline": { "local": [ "tm2411306d1_8k.htm" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://milestonepharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2411306d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2411306d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001104659-24-044767-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-044767-xbrl.zip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end XML 19 tm2411306d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001408443 2024-04-08 2024-04-08 iso4217:USD shares iso4217:USD shares false 0001408443 A8 00-0000000 QC 8-K 2024-04-08 MILESTONE PHARMACEUTICALS INC. 001-38899 1111 Dr. Frederik-Philips Boulevard Suite 420 Montréal CA H4M 2X6 514 336-0444 false false false false Common Shares MIST NASDAQ true true